The development of the anti-TB drug bedaquiline introduced both a novel chemical class—diarylquinolines (DARQs)—as well as a novel M. tb-selective mechanism of action (direct inhibition of M. tb ATP synthase). This next-generation diarylquinoline project has shown potential to maintain bedaquiline’s impressive anti-TB activities while introducing improved safety properties.